Horus Pharma

Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France

23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of Formycon’s Eylea biosimilar FYB203 (Aflibercept) under the brand name Baiama...
22 allée Camille MUFFAT - Inedi 5 06200 Nice

+33 4 93 19 54 03